| Name | Title | Contact Details |
|---|
Sertech is a Batavia, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The Nature`s Bounty Co. has a history of championing health and wellness tracing back 145 years. Putting science and the highest quality standards at the heart of our business, the brands of The Nature`s Bounty Co. are some of the most trusted in the world. Always motivated by our commitment to excellence, our vision for health and wellness has inspired leading brands such as Nature`s Bounty, Sundown Naturals, Solgar, Holland & Barrett, Osteo Bi-Flex, Ester-C, MET-Rx, Pure Protein, Balance, Body Fortress, Puritan`s Pride and Organic Dr., among others. As a leading global manufacturer, marketer, distributor and retailer of vitamins, nutritional supplements, sports & active nutrition and ethical beauty products, The Nature`s Bounty Co. is committed to supporting wellness in all its forms.
Monitored Therapeutics Inc. is focused on solutions for the management of respiratory diseases like COPD, Asthma, Lung Transplant, and Cystic Fibrosis.
LeafLine Labs was founded by practicing physicians who see the unnecessary suffering patients endure every day. We are, first and foremost, caregivers who exist to give our patients the quality of life they deserve.
ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics to treat severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS® platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH`s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival. The Company`s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cell`s altered asparagine and glutamine metabolism. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in Phase 2 for the treatment of triple-negative breast cancer. ERYTECH is based in Lyon, France and Cambridge, MA, USA, and has manufacturing sites in Lyon, France, and Princeton, New Jersey, USA.